Betta Pharmaceuticals Co., Ltd.

SZSE:300558 Stock Report

Market Cap: CN¥22.8b

Betta Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Lieming Ding

Chief executive officer

CN¥2.9m

Total compensation

CEO salary percentagen/a
CEO tenure11.3yrs
CEO ownership0.2%
Management average tenureno data
Board average tenure5.1yrs

Recent management updates

Recent updates

Is Now The Time To Put Betta Pharmaceuticals (SZSE:300558) On Your Watchlist?

Dec 17
Is Now The Time To Put Betta Pharmaceuticals (SZSE:300558) On Your Watchlist?

Does Betta Pharmaceuticals (SZSE:300558) Have A Healthy Balance Sheet?

Nov 26
Does Betta Pharmaceuticals (SZSE:300558) Have A Healthy Balance Sheet?

We Think That There Are Some Issues For Betta Pharmaceuticals (SZSE:300558) Beyond Its Promising Earnings

Nov 04
We Think That There Are Some Issues For Betta Pharmaceuticals (SZSE:300558) Beyond Its Promising Earnings

Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce

Sep 30
Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 07
Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

Jul 30
Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Jul 05
These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Apr 26
Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Apr 23
Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Apr 16
What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

CEO

Lieming Ding (61 yo)

11.3yrs

Tenure

CN¥2,900,800

Compensation

Dr. Lieming Ding founded Betta Pharmaceuticals Co., Ltd.(also known as Zhejiang BetaPharma Co., Ltd) in 2002 and serves as its Chairman. Dr. Ding has been Chief Executive Officer and General Manager of Bet...

Board Members

NamePositionTenureCompensationOwnership
Lieming Ding
Founderno dataCN¥2.90m0.24%
CN¥ 53.8m
Jianxun Fan
VP, CFO & Directorno dataCN¥1.46m0.031%
CN¥ 7.1m
Jiang Wan
Senior VP5.1yrsCN¥2.55m0.025%
CN¥ 5.7m
Jia Tong
Directorno dataCN¥1.46m0.039%
CN¥ 9.0m
Wei Wang
Independent Director5.1yrsCN¥120.00kno data
Cai Jiangnan
Independent Director5.1yrsCN¥120.00kno data
Yangnan Zhang
Chairman of the Supervisory Board & Senior Director of Project Declaration5.1yrsCN¥870.70kno data
Zhihua Yu
Director5.1yrsno datano data
Tian Xu
Director2.2yrsno datano data
Fei Wu
Supervisorno dataCN¥860.20kno data
Jiajia Xiao
Independent Director2.2yrsCN¥120.00kno data
Rong Wang
Shareholder Supervisor2yrsno datano data

5.1yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 300558's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 22:51
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Betta Pharmaceuticals Co., Ltd. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue GaoChangjiang Securities Co. LTD.
Jin ZhangChina International Capital Corporation Limited
Jing QiangChina International Capital Corporation Limited